The Diversity of Liquid Biopsies and Their Potential in Breast Cancer Management

Overview

Journal Cancers (Basel)

Publisher MDPI

Specialty Oncology

Date 2023 Nov 25

PMID 38001722

Authors

Corinna Keup

Rainer Kimmig

Sabine Kasimir-Bauer

Affiliations

Soon will be listed here.

Abstract

Analyzing blood as a so-called liquid biopsy in breast cancer (BC) patients has the potential to adapt therapy management. Circulating tumor cells (CTCs), extracellular vesicles (EVs), cell-free DNA (cfDNA) and other blood components mirror the tumoral heterogeneity and could support a range of clinical decisions. Multi-cancer early detection tests utilizing blood are advancing but are not part of any clinical routine yet. Liquid biopsy analysis in the course of neoadjuvant therapy has potential for therapy (de)escalation.Minimal residual disease detection via serial cfDNA analysis is currently on its way. The prognostic value of blood analytes in early and metastatic BC is undisputable, but the value of these prognostic biomarkers for clinical management is controversial. An interventional trial confirmed a significant outcome benefit when therapy was changed in case of newly emerging cfDNA mutations under treatment and thus showed the clinical utility of cfDNA analysis for therapy monitoring. The analysis of PIK3CA or ESR1 variants in plasma of metastatic BC patients to prescribe targeted therapy with alpesilib or elacestrant has already arrived in clinical practice with FDA-approved tests available and is recommended by ASCO. The translation of more liquid biopsy applications into clinical practice is still pending due to a lack of knowledge of the analytes' biology, lack of standards and difficulties in proving clinical utility.

Citing Articles

Circulating Tumor DNA in Early and Metastatic Breast Cance-Current Role and What Is Coming Next.

Tegeler C, Hartkopf A, Banys-Paluchowski M, Krawczyk N, Fehm T, Jaeger B Cancers (Basel). 2024; 16(23).

PMID: 39682108 PMC: 11640659. DOI: 10.3390/cancers16233919.

Male Breast Cancer: Current Scenario and Future Perspectives.

Chidambaram A, Prabhakaran R, Sivasamy S, Kanagasabai T, Thekkumalai M, Singh A Technol Cancer Res Treat. 2024; 23:15330338241261836.

PMID: 39043043 PMC: 11271170. DOI: 10.1177/15330338241261836.

Circulating tumor cells : towards a comprehensive liquid biopsy approach in breast cancer.

Nicolo E, Gianni C, Pontolillo L, Serafini M, Munoz-Arcos L, Andreopoulou E Transl Breast Cancer Res. 2024; 5:10.

PMID: 38751670 PMC: 11093063. DOI: 10.21037/tbcr-23-55.

Research progress of CTC, ctDNA, and EVs in cancer liquid biopsy.

Wang X, Wang L, Lin H, Zhu Y, Huang D, Lai M Front Oncol. 2024; 14:1303335.

PMID: 38333685 PMC: 10850354. DOI: 10.3389/fonc.2024.1303335.

References

Hrebien S, Citi V, Garcia-Murillas I, Cutts R, Fenwick K, Kozarewa I . Early ctDNA dynamics as a surrogate for progression-free survival in advanced breast cancer in the BEECH trial. Ann Oncol. 2019; 30(6):945-952. PMC: 6594458. DOI: 10.1093/annonc/mdz085. View

Tewes M, Aktas B, Welt A, Mueller S, Hauch S, Kimmig R . Molecular profiling and predictive value of circulating tumor cells in patients with metastatic breast cancer: an option for monitoring response to breast cancer related therapies. Breast Cancer Res Treat. 2008; 115(3):581-90. DOI: 10.1007/s10549-008-0143-x. View

Gennari A, Andre F, Barrios C, Cortes J, de Azambuja E, DeMichele A . ESMO Clinical Practice Guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer. Ann Oncol. 2021; 32(12):1475-1495. DOI: 10.1016/j.annonc.2021.09.019. View

Suppan C, Brcic I, Tiran V, Mueller H, Posch F, Auer M . Untargeted Assessment of Tumor Fractions in Plasma for Monitoring and Prognostication from Metastatic Breast Cancer Patients Undergoing Systemic Treatment. Cancers (Basel). 2019; 11(8). PMC: 6721524. DOI: 10.3390/cancers11081171. View

Bourrier C, Pierga J, Xuereb L, Salaun H, Proudhon C, Speicher M . Shallow Whole-Genome Sequencing from Plasma Identifies FGFR1 Amplified Breast Cancers and Predicts Overall Survival. Cancers (Basel). 2020; 12(6). PMC: 7353062. DOI: 10.3390/cancers12061481. View

Larsson A, Jansson S, Bendahl P, Jorgensen C, Loman N, Graffman C . Longitudinal enumeration and cluster evaluation of circulating tumor cells improve prognostication for patients with newly diagnosed metastatic breast cancer in a prospective observational trial. Breast Cancer Res. 2018; 20(1):48. PMC: 5994056. DOI: 10.1186/s13058-018-0976-0. View

Cristofanilli M, Budd G, Ellis M, Stopeck A, Matera J, Miller M . Circulating tumor cells, disease progression, and survival in metastatic breast cancer. N Engl J Med. 2004; 351(8):781-91. DOI: 10.1056/NEJMoa040766. View

Hartkopf A, Stefanescu D, Wallwiener M, Hahn M, Becker S, Solomayer E . Tumor cell dissemination to the bone marrow and blood is associated with poor outcome in patients with metastatic breast cancer. Breast Cancer Res Treat. 2014; 147(2):345-51. DOI: 10.1007/s10549-014-3113-5. View

. . Med Genet. 2024; 34(1):53-68. PMC: 11110128. DOI: 10.1515/medgen-2022-2112. View

10.

Jongbloed E, Deger T, Sleijfer S, Martens J, Jager A, Wilting S . A Systematic Review of the Use of Circulating Cell-Free DNA Dynamics to Monitor Response to Treatment in Metastatic Breast Cancer Patients. Cancers (Basel). 2021; 13(8). PMC: 8069506. DOI: 10.3390/cancers13081811. View

11.

Shaw J, Guttery D, Hills A, Fernandez-Garcia D, Page K, Rosales B . Mutation Analysis of Cell-Free DNA and Single Circulating Tumor Cells in Metastatic Breast Cancer Patients with High Circulating Tumor Cell Counts. Clin Cancer Res. 2016; 23(1):88-96. PMC: 6241844. DOI: 10.1158/1078-0432.CCR-16-0825. View

12.

Budd G, Cristofanilli M, Ellis M, Stopeck A, Borden E, Miller M . Circulating tumor cells versus imaging--predicting overall survival in metastatic breast cancer. Clin Cancer Res. 2006; 12(21):6403-9. DOI: 10.1158/1078-0432.CCR-05-1769. View

13.

OLeary B, Cutts R, Huang X, Hrebien S, Liu Y, Andre F . Circulating Tumor DNA Markers for Early Progression on Fulvestrant With or Without Palbociclib in ER+ Advanced Breast Cancer. J Natl Cancer Inst. 2020; 113(3):309-317. PMC: 7936069. DOI: 10.1093/jnci/djaa087. View

14.

Chen Z, Sun T, Yang Z, Zheng Y, Yu R, Wu X . Monitoring treatment efficacy and resistance in breast cancer patients via circulating tumor DNA genomic profiling. Mol Genet Genomic Med. 2019; 8(2):e1079. PMC: 7005625. DOI: 10.1002/mgg3.1079. View

15.

Elliott M, Cescon D . Development of novel agents for the treatment of early estrogen receptor positive breast cancer. Breast. 2021; 62 Suppl 1:S34-S42. PMC: 9097798. DOI: 10.1016/j.breast.2021.11.007. View

16.

Bryce A, Thiel D, Seiden M, Richards D, Luan Y, Coignet M . Performance of a Cell-Free DNA-Based Multi-cancer Detection Test in Individuals Presenting With Symptoms Suspicious for Cancers. JCO Precis Oncol. 2023; 7:e2200679. PMC: 10581635. DOI: 10.1200/PO.22.00679. View

17.

Fernandez-Garcia D, Hills A, Page K, Hastings R, Toghill B, Goddard K . Plasma cell-free DNA (cfDNA) as a predictive and prognostic marker in patients with metastatic breast cancer. Breast Cancer Res. 2019; 21(1):149. PMC: 6924016. DOI: 10.1186/s13058-019-1235-8. View

18.

Gonzalez-Masia J, Garcia-Olmo D, Garcia-Olmo D . Circulating nucleic acids in plasma and serum (CNAPS): applications in oncology. Onco Targets Ther. 2013; 6:819-32. PMC: 3711950. DOI: 10.2147/OTT.S44668. View

19.

Mao P, Cohen O, Kowalski K, Kusiel J, Buendia-Buendia J, Cuoco M . Acquired FGFR and FGF Alterations Confer Resistance to Estrogen Receptor (ER) Targeted Therapy in ER Metastatic Breast Cancer. Clin Cancer Res. 2020; 26(22):5974-5989. DOI: 10.1158/1078-0432.CCR-19-3958. View

20.

Stevic I, Muller V, Weber K, Fasching P, Karn T, Marme F . Specific microRNA signatures in exosomes of triple-negative and HER2-positive breast cancer patients undergoing neoadjuvant therapy within the GeparSixto trial. BMC Med. 2018; 16(1):179. PMC: 6178264. DOI: 10.1186/s12916-018-1163-y. View